Case concerns right of U.S. health information provider NDCHealth to demand a licence to the marketing database of rival IMS Health.
In a setback for large pharma and biotech companies, alternative route could be used to approve the first generation of generic biotechnology drugs.
Roxane drops challenge to patent and agrees not to seek approval to market product until patent expires in 2014.
In a highly unusual turn of events, lawyers for two companies in a patent dispute have themselves been pulled into the litigation.
Lundbeck agrees to licence patents to Sandoz for certain territories and pulls claims of forgery and perjury against Matrix Laboratories.
Ortho Tri-Cyclen Lo oral contraceptive has $110 million in annual sales.
Genzyme had already withdrawn from suit in settlement one day earlier; Mount Sinai not expected to pursue case further.
Vast majority of patent examiners work on information technology innovations.
Ruling comes only one day after a U.S. court upholds patent related to Replagal.
Drug maker claims claims local rivals are pressuring the government to slow implementation on data exclusivity.
Biotech company claims University of Michigan scientist played pivotal role in discovery of compound to treat rheumatoid arthritis.
Biotech experts are urging Taiwan to protect research data on new uses for drugs with expired patents.
Summary judgment finds Teva infringed patents in dispute over blood pressure medicine Accupril.
Nutra receives unlimited licensing rights to several Bio patents.
Trial over remaining disputes with Mylan Laboratories to begin within six months.